LIF exerts these effects through its binding onto its receptor, LIFR, expressed on different cell types such as hepatocytes, which is down-regulated in the obese state and NAFLD patients [40]. This evidence concerns the gene LIF and metabolic dysfunction-associated steatotic liver disease.